XXXXXXXX KOMISE X XXXXXXXXX XXXXXXXXX (XX) x. 1062/2014
xx dne 4. xxxxx 2014,
xxxxxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxx všech stávajících xxxxxxxx látek obsažených x xxxxxxxxxx xxxxxxxxxxx, xxxxx xxxx xxxxxxx x xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012
(Xxxx x xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x xxxxxxx xx Xxxxxxx o fungování Xxxxxxxx xxxx,
x xxxxxxx xx xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 528/2012 xx xxx 22. xxxxxx 2012 x xxxxxxxx xxxxxxxxxx přípravků xx xxx x jejich xxxxxxxxx (1), x zejména xx čl. 89 xxxx. 1 první xxxxxxxxxxx uvedeného xxxxxxxx,
vzhledem x těmto xxxxxxx:
(1) |
Xxxxxxxx Xxxxxx (ES) č. 1451/2007 (2) xxxxxxx xxxxxxxxx pravidla xxx xxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx účinných xxxxx (dále xxx „xxxxxxx xxxxxxxx“), který xxx zahájen x xxxxxxx x xx. 16 xxxx. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX (3). Xxxxxxx tato xxxxxxxx byla xxxxxxx x xxxxxxxxx xxxxxxxxx (EU) x. 528/2012, měla by xxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx xxxxxxxx přizpůsobena ustanovením xxxxxxxxx nařízení. |
(2) |
Je xxxxxxxx xxxxx kombinace xxxxxx xxxxx a xxxx xxxxxxxxx, xxxxx xxxxx xxx xxxxxxxx na trh x xxxxxxxxx xxxxx přechodných xxxxxxxxxx článku 89 xxxxxxxx (XX) x. 528/2012 s výhradou xxxxxxxxxxxxxx předpisů. Mělo xx xxxx xxx x v xxxxxxx xxxxxxxxx xxxxxx látky x typu xxxxxxxxx, xxxxx xxxx xxxxxxxxx x xxxxxxxx přezkumu. |
(3) |
Pokud xxxxxxxxx xxxxxxxx xxxxxxxx xxx xxxxxxxxx x xxxxxx xxxxx článku 6 xxxxxxxx (XX) č. 1451/2007, xxx xxxxxxxxxx se xx něj xxxxxxx xxx xxxxxxxxx x xxxxxx xxxxxxx x xx. 2 xxxx. 5 xxxx. x) xxxxxxxx (XX) x. 528/2012, xxxx by xxx xxxxxx látky, xxxxx xxxxxxxx, xxxxxxxxx x xxxxxxxx přezkumu xxx xxxxxxxxx typ xxxxxxxxx. X xxxxxxxx xxxxxxxxxxxxxx předpisů xx xxxx být xxxxxx xxxxxxxx xx xxx x xxxxxxxxx xxxxxxxx xx xx xxxxxxxx xxxxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxx prohlášení xx xxx xxxxxxx, xxxxx xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxx. Xxxxx xx xxxx xxxxxx x xxxxxxxxx, xxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxx x xxxx xxxxxxxxx vyplynulo x xxxx xxxxxxxx xxxx přípravků x xxxxxxxx (XX) x. 528/2012 xxxxxx xxxxxxxx xxxxxxx ve xxxxxxxx 98/8/XX nebo xx řádně xxxxxxxxxx xxxxxxxxxxx Komise xxxxxxxx x xxxxxxx s čl. 3 xxxx. 3 xxxxxxxx (XX) č. 528/2012, xxxxxxxxxxx (xxxxxxxxx rozhodnutím xx věci C-420/10 (4)) xxxx závaznými pokyny Xxxxxx xx xxxxxxxxxxx xxxxxx xxxxxxxxx států, xxxxx xx xxxxxxxx xxxxxxx. |
(4) |
Xxxxx biocidní xxxxxxxxx xxxxxxxx účinnou xxxxx, xxxxx již xxxx xxxxxxxx xx xxxxxxxx xxxxxxxx, z xxxx xxxxx sestává xxxx xx x xx xxxxxx, xxxxx xxxxxxxx xx xxxxxxxxx xxxxxx xxxxxxxxxx přípravku v členském xxxxx xxxxxxxx, xxxx xx xxx x xxxxx xxxxxxxx xxxxx xxxxxxx x dodávání xx xxx xxxxxxxx na xxxx xxxxxxxxxxxx, za určitých xxxxxxxx a po xxxxxxxx xxxx. |
(5) |
X xxxxx jednotnosti x xxxxxxxxxxxx xx xxx xxx xxxxxx xxxxxxxxx xxxxxxxx xxxxx v programu xxxxxxxx xx xxxxx xxxxxxxxxx částech xxxxxxx x xxxxxxxx stanoveným xxx xxxxxxx xxxxxxxxxx xxxxx xxxxxx 7 xxxxxxxx (XX) č. 528/2012 xxxx xxxxx prováděcího xxxxxxxx Xxxxxx (EU) x. 88/2014 (5). |
(6) |
Xxx xxxxx, které xxxxxxx xxxxxxxx xxxxxxxxx xxxx xxxxxxxx xxx xxxxxxx, xx xxx xxxxxxxxx xxxxxxxxx xxxxx předložit xxxxxxxx xxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx látky xxxxx xx. 37 odst. 1 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 (6), xxxxx xxx x xxxxxxxxx vlastnosti xxxxxxxxxx xxxxx, x xxxxxxx xx xxxx xxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxxxxx xx xxxxxx nebo xxxxx xxxxxxxxxxx xxxxxxxxxx. Xxxxxxxxx xxxxxxxxx xxxxx xx xxx xxxx xxxxxxxxxxx agenturu x xxxxxxx xxxxx, xxxxx xx xxxxxxxxx xxxxxxxx xxx xxxxx perzistentní, xxxxxxxxxxxxxxx xx xxxxxxx, xxxx xxxxx, které xx xxxxx být xxxxxxxxxx xx látky s vlastnostmi xxxxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx. |
(7) |
Xxx bylo xxxxxxxxx, xx xxxxxxx xxxxxxxx xxxx xxxxxxxx do xxxxxxxx data xxxxxxxxx x xx. 89 odst. 1 nařízení (XX) x. 528/2012, xxxx xx xx hodnocení xxxxxx na kombinace xxxxxx látky x xxxx xxxxxxxxx, x xxxxx xxxx xxxxxxxxx xxxxx xxxxxxxxxx ve lhůtách stanovených x xxxxxxxx (XX) č. 1451/2007 xxxx v tomto nařízení. Xxxxx xxxx by xx xxxx xxxxxxxx xxxxxx xxxxx xxx xxxxxxxxx xxxxxxxxx, xxxxxxx xx xx xxxx xxxx v xxxxx xxxxxxx, xx xxxxxxx xx mohly být xxxxxxxxx méně xxx xxx před uplynutím xxxxxx xxxx. |
(8) |
Xxxxxxx zařazení xx xxxxxxx X xxxxxxxxx 7 xxxxxxxx (XX) x. 528/2012 xxxxx xxxxxx stanoveny xxxxx xxxxxxxxx xx xxxxx. Xx xxxxx xxxxxx x této fázi xxxxxx xxxxxxx x xxxxxxxx xx xxxxxxx xxxxxxx xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6. |
(9) |
Xxx xxxxxx na čl. 90 odst. 2 xxxxxxxx (XX) x. 528/2012 xxxxxxx z článku 91 xxxxxxxxx xxxxxxxx, xx xxxxxxxx uvedená x xxxxxx 10 xxxxxxxxx xxxxxxxx xx xxxx xxx xxxxxxxxxx xxx následné xxxxxxxxxx xxxxxxxxxx přípravků xx xxxxx xxxxxxxxx. Je proto xxxxxx xxxxx xxxxx xxxxxxxxx xxxx xxxxxxxx xx xxxxx hodnoceních xxxxxxxx xxxxx. |
(10) |
Xxxxxxxxxxx účastník xxxxxxxx xxxxxxxx xx xxx xxx možnost xx xx vzájemné xxxxxx xxxxxxxx xx stávajícímu xxxxxxxxxxx nebo jej xxxxxxxx za předpokladu, xx xxxxx xxxx xxxxxxx xx zpoždění xxxxxxxxx z důvodu xxxxxxxxx xxxxxxxx x xxxxxx, xxxxxxx xxxxx xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx xxxxx xxxxx. |
(11) |
Xxxxxxx xx xxxxx v programu xxxxxxxx xxxxxxxxxx, xxxx xx xxx xxxxxxxxxx xxxxxxxx od xx xxxxxxxxx. Xxxxx k xxxx xxxxx, xxxx xx xxx xxxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxx xxxxxxx, nebylo-li této xxxxxxxx využito xxx xxxxxx, xxxxx xxx xxxxxxx xx zpoždění xxxxxxxx xxxxxxxx, x xxxxxxxx-xx xxxxxxxx xxx xxxxxxxx xx svém xxxxxxxxxx. |
(12) |
Xxxxx xx xxx xxxxxxxxx účinné xxxxx xxxxx, xx xxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxxxx xxxxxx xxxxxxxxxx identitě xxxxxxxx xxxxxxxxx xxxxx, x x xxxxxxxxx xxxxx xxxxxxx xxxxxx xxxxxxx xxxxxxxx oficiálně xxxxxxxx xxxxx, xxxx by xxx xxxxx xxxx xxxxx x xxxxxxx xxxxxxxxx xxxxx xxxxxxxxx a povolit xxxxx osobám, xxx xxxxxxxx xxxxxxx této xxxxxxxxx xxxxxxxx látky. |
(13) |
Některé xxxxx xxxxxxxx do xxxxxxxx xxxxxxxx nejsou x xxxx xxxxxxx xxxxxx xxxxxxxx podporovány xxxxxx xxxxxxxxxx. Totéž xx týká určitých xxxxxxxxxxxxx, ačkoli xxxxx xx. 4 odst. 4 xxxxxxxx (XX) x. 528/2012 xxxx xxxxxxxxx nelze xxxxxxxx, xxxxx xxx není xxxxxxxx xxxxxxxxx. X xxxxxxxxx látek x xxxxxxxxxxxxx xx xxxx xxx osoby xxxxxxx xxxxxxx účast, xxxxxxx xxxxx by xxxx xxxxx x xxxxxxxxxxxxx musely xxx x xxxxxxxx xxxxxxxx vyloučeny. |
(14) |
Xxx xxxx xxxxxxxxx, xx xxxxx xxxxx nezůstane x xxxxxxxx xxxxxxxxxxx xxx xx něj xxxxxx xxxxxxxx, aniž xx xxxxxxxx byla vyhodnocena, xxxx xx setrvání xxxxx, xxxxx xxxxx xxxxxx hodnocena, x xxxxxxxx nebo xxxx xxxxxxxx xxxxxxxx oznamování xxxxxxxxxx údajů o xx, |
XXXXXXX TOTO XXXXXXXX:
XXXXXXXX 1
PŘEDMĚT X XXXXXXXX
Xxxxxx 1
Xxxxxxx
Xxxx xxxxxxxx xxxxxxx pravidla pro xxxxxxxxx pracovního programu xxxxxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx v článku 89 xxxxxxxx (XX) x.&xxxx;528/2012.
Xxxxxx 2
Xxxxxxxx
Pro účely xxxxxx nařízení se xxxxxxx tyto definice:
x) |
„xxxxxxxxxxx x neschválení“ xx xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx a typu xxxxxxxxx xxxxx xx. 9 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012 nebo xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx, xxxx xxxxxxxxx nezařadit xx xxxxxxx I nebo IA xxxxxxxx 98/8/ES; |
x) |
„xxxxxxxxx látky x xxxx přípravku zařazenou xx xxxxxxxx xxxxxxxx“ xx xxxxxx kombinace xxxxx x xxxx xxxxxxxxx xxxxxxx x xxxxxxx II, která xxxxxxx xxxx xxxxxxxx:
|
c) |
„xxxxxxxxxx“ xx xxxxxx osoba, xxxxx xxxxxxxxxx žádost x xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxx do programu xxxxxxxx xxxx předložila xxxxxxxx, které xxxxxxxx xxxxxxxxxx podle čl. 17 xxxx. 5 xxxxxx xxxxxxxx, xxxx jejímž xxxxxx xxxx xxxx žádost xxxx oznámení xxxxxxxxxx; |
d) |
„xxxxxxxxxx xxxxxxxxxx xxxxxxx“ xx xxxxxx xxxxxxxxx xxxxx xxxxxxxxx státu xxxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, určený x xxxxxxx s článkem 81 nařízení (XX) x. 528/2012. |
XXXXXXXX 2
POSTUP XXXXXXXXX XXXXXXXXXXX
Xxxxxx 3
Xxxxxx x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxx X xxxxxxxx (XX) č. 528/2012
1.&xxxx;&xxxx;&xxxx;Xxxxxx x&xxxx;xxxxxxxxx xx xxxxxxxx do přílohy I nařízení (XX) č. 528/2012 xxxx xxxxx xxxxx xxxxxxxx, x xxxxx xxxxxxxx xxxxx agentura k xxxxxx, xx xxxxxxxx xxxxxxxxxx xxxxx xx.&xxxx;17 xxxx.&xxxx;5 xxxxxx xxxxxxxx.
Xxxxx xx xxxxxx týká xxxxxxxx xx&xxxx;xxxxxxx X&xxxx;xxxxxxxx (XX) x.&xxxx;528/2012, může xx týkat pouze xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 xxxxxxx xxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxxxxx x&xxxx;xxxxxxxx 1 xx podávají xxxxxxxx xx&xxxx;xxxx xxx xx xxxxxxxxxx x&xxxx;xxxxxxx x požadavky podle xx.&xxxx;17 xxxx.&xxxx;5.
Xxxxxx 4
Xxxxxxx žádostí
1. Xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx Xxxxxx (XX) x. 564/2013 (7) x zamítne xxxxxx, xxxxx účastník xxxxxxxxx xxxxxxxx xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx i xxxxxxxxx xxxxxxxxx xxxxx.
2. Po xxxxxxxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 564/2013 xxxxxx xxxxxxxx žádost a informuje x tom xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxx xxxxx xxxxx xxxxxxx žádosti x xxxx xxxxxxxxx xxxxxxxxxxxxx xxx.
3. Proti xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 1 xxxxxx xxxxxx xxx xxxxx xxxxxxx prostředek v xxxxxxx x článkem 77 xxxxxxxx (EU) x. 528/2012.
4. Xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx účastníka x xxxxxxxx xxxxxxxx xxxxx xx. 80 xxxx. 2 nařízení (XX) x. 528/2012 xx 30 dnů xxxx, xx agentura xxxxxxx žádost, x xxxxxxx žádost, pokud xxxxxxxx xxxxxxxxx poplatek xx xxxxx 30 xxx. O xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx.
Xxxxxx 5
Xxxxxxxxx xxxxxxx x xxxxxxxxx nebo xxxxxxxx xx xxxxxxxxx 6 xxxxxxx X xxxxxxxx (EU) x. 528/2012
1. Xxxxx xxxxxxxx přijme xxxxx xx. 4 xxxx. 2 žádost x xxxxxxxxx xxxx xxxxxxxx xx xxxxxxxxx 6 přílohy X xxxxxxxx (EU) x. 528/2012, xxxxx xxxxxxxx xxxxx xxxxxxxxxx x xxxxxxx s čl. 6 xxxx. 1 a 2 xxxxxxxxx nařízení, a byl xxxxxxxx poplatek xxxxx xx. 4 xxxx. 4, hodnotící xxxxxxxxx xxxxx xxxxxx xxxxxxx xx 30 xxx xx xxxxxxxxx poplatků.
2. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx nařízení (XX) x. 1451/2007, avšak xx xxxxx xxxxxx xxxxxx xxxx úplná xxxxx xxxxxx 13 uvedeného xxxxxxxx, xxxxxxx hodnotící xxxxxxxxx xxxxx xxxxxx xxxxxxxxxx xx 3. xxxxx 2015.
3. X xxxxxxxxx xxxxxxxxx x xxxxxxxxxx 1 x 2 hodnotící xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxxx xxx xxxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxx odůvodnění.
4. Pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxx, xx xxxxxx je xxxxxxx, xxxxx xxxxxxxxxxx, xxxx xxxxxxxxxx xxxxxxxxx xxxx x xxxxxxxxx xxxxxxx xxxxx, a x xxxxxxxxxx xxxxxx xxxxxxxxx xxxxxxx přiměřenou xxxxx. Tato lhůta xxxxx xxxxxxxxxx 90 dnů.
Xxxxxxxx-xx xxxxxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx postačují ke xxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx 2, xxxxxxx žádost xx 30 xxx od xxxxxxxx xxxxxxxxxxxx informací.
Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxxx, xxxxxxxxx xxxxxxxxx xxxxx xxxxxx xxxxxxx x informuje x xxxx skutečnosti xxxxxxxxx x xxxxxxxx. X xxxxxx případech se xxxxx poplatky xxxxxxxxx x xxxxxxx x xx. 80 xxxx. 1 x 2 xxxxxxxx (XX) x. 528/2012.
Xxx potvrzení xxxxxxx xxxxxxxxx příslušný xxxxx xxxxxxxxxx informuje xxxxxxxxx, xxxxxxxx a další xxxxxxxxx xxxxxx a uvede datum xxxxxx xxxxxxxxx.
Xxxxxx 6
Xxxxxxxxx žádostí
1. Tento xxxxxx xx xxxxxxx, xxxxx platí některá x xxxxxx xxxxxxxx:
a) |
je-li žádost xxxxxxxxx podle xxxxxx 5; |
x) |
xxxxx xxxxxxxxx xxxxxxxxx xxxxx uznal xxxxxxxxxxx xxxx úplnou podle xxxxxx 13 xxxxxxxx (XX) x. 1451/2007, xxx xxxxx xxxxxxxxxxx Xxxxxx xxxxxx xxxxxxxxxxx xxxxxx podle xx. 14 odst. 4 xxxxxxxxx xxxxxxxx; |
x) |
xxxxx xxxxxxxx přijala xxxxxx x xxxxxxxx xx xxxxxxxxx 1, 2, 3, 4 xxxx 5 xxxxxxx X xxxxxxxx (XX) č. 528/2012 podle xx. 4 xxxx. 2 a xxx zaplacen xxxxxxxx xxxxx xx. 4 odst. 4. |
2. Xxxxxxxxx xxxxxxxxx orgán xxxxxxxx xxxxxx xxxxx xxxxxx 4 x 5 xxxxxxxx (XX) č. 528/2012 x případně xxx xxxxxxx xxxxxx xx xxxxxx požadavků xx údaje xxxxxxxxxx x xxxxxxx s xx. 6 odst. 3 uvedeného xxxxxxxx x xxxxx hodnotící xxxxxx a xxxxxx xxxxx hodnocení xxxxxxxx.
3. Pokud xxxxxxx kombinaci xxxxx x xxxx přípravků xxxxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxxxxxxx příslušný xxxxx xxxxx xxxxx xxxxxxxxx xxxxxx. Xxxxxxxxx xxxxxx a závěry xxxxx x xxxxx x xxxxxx xxxx, podle xxxx, xx xxxxxxx později:
x) |
365 xxx xx xxxxxxxxx xxxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x), uznání xxxxxxxx xxxxxxxx x xxxx. 1 xxxx. x) xxxx xxxxxxxxx xxxxxxxx xxxxxxxxx v odst. 1 xxxx. x) x dotyčné xxxxxxxxx xxxxx x xxxx přípravku; |
x) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
4. Xxxx xxx, xxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxx své xxxxxx xxxxxxxx, umožní účastníkovi xxxxx xx 30 xxx x hodnotící xxxxxx x k xxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxx. Xxxxxxxxx příslušný xxxxx xxxx připomínky xxxxxxxxxxxxx xxxxxxxx zohlední x závěrečné xxxx xxxxx hodnocení.
5. Xxxxx xx xxxxx, xx xxxx x xxxxxxxxx xxxxx xxxxxxxxxx informace, xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxx, xxx tyto xxxxxxxxx xx xxxxxxxxx xxxxx xxxxxxxxx, x xxxxxxxxx x xxx xxxxxxxx.
Xxxxx 365 dnů xxxxxxx v xxxxxxxx 3 xx xxxxxxx xx xxxx xxx xxx xxxxxxxx požadavku xx dne xxxxxxxx xxxxxxxxx. Pokud xx xxxx odůvodněno xxxxxxx xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxx, přerušení xxxxxxxxxx následující lhůty:
a) |
365 xxx v případě, xx xx doplňující xxxxxxxxx xxxxxx xxxxxx, xxxxx xxxxxx xxxxxx x xxxxx směrnice 98/8/XX xxxx v rámci postupů xxxxxxxxxxx xxx xxxxxxxxxxx xxxxxxx xxxxxxxx; |
x) |
180 dní xx xxxxx xxxxxxxxx xxxxxxxxx. |
6. Pokud xxxxxxxxx xxxxxxxxx orgán xxxxxx, xx xxxxxxxx xxxxx xxxxxxx xxxxxx xxxx xxxx xxxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxx x xxxxxxxxxxxxx účinků xxxxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx stejné xxxx xxxxxxxx xxxxxx xxxxx, xxx xxxxx xxxxxxxxxxxx x xxxxxxx x xxxxxxxxx příslušných xxxxx xxxxxx XX xxxx 3 xxxxxxx XX nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (8) x xxxxxx xx xx xxxxx xxxxxx.
7. X xxxxxxx potřeby xx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx bez zbytečného xxxxxxx x xxxxxxxxxx xxx xxxxxxxxxx hodnotící xxxxxx xxxxx xxxxxxxx 3:
x) |
předloží xxxxx xxxxxxxx xxxxx xx. 37 xxxx. 1 xxxxxxxx (XX) x. 1272/2008, xxxxxxxx xx xxxxxxx, xx xx xxxxxxx jedno z kritérií xxxxxxxxx x xx. 36 odst. 1 xxxxxxxxx nařízení, ale xxxx náležitě xxxxxx x xxxxx 3 xxxxxxx XX xxxxxxxxx xxxxxxxx; |
b) |
xxxxxxxxxx s agenturou, xxxxx xx xxxxxxx, xx xxxxx z kritérií xx. 5 xxxx. 1 písm. d) xxxx x) xxxxxxxx (EU) x. 528/2012 xxxx xxxxxxxx xx. 10 odst. 1 xxxx. x) xxxxxxxxx xxxxxxxx jsou xxxxxxx, ale xxxxxx xxxxxxxx řešeny v příloze XXX xxxxxxxx (ES) x. 1907/2006 nebo x xxxxxxx xxxxxxxx v čl. 59 xxxx. 1 xxxxxxxxx xxxxxxxx. |
Xxxxxx 7
Xxxxxxxxxx xxxxxxxx
1. Tento xxxxxx se xxxxxxx, xxxxx platí xxxxxxx x xxxxxx xxxxxxxx:
x) |
pokud xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxxx xxxxxx podle xx. 6 xxxx. 2 x xxxxxxxx xxxxxxxxx xxxxx xxxx xxxxxxx konzultaci xxxxx xx. 6 xxxx. 7; |
b) |
pokud xxxx xxxxxxxxxx Komisi xxxxxx příslušného xxxxxx xxxxx čl. 14 xxxx. 4 xxxxxxxx (ES) x. 1451/2007, xxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxxxxx Xxxxx xxxxx xxx biocidní xxxxxxxxx podle xx. 15 xxxx. 4 xxxxxxxxx xxxxxxxx. |
2. Xx xxxxxxx xxxxxx agentura xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxx x xxxx přípravku xxxx xxxx zařazení xx xxxxxxxxx 1, 2, 3, 4, 5 xxxx 6 přílohy X xxxxxxxx (EU) č. 528/2012, xxxxxxxx xxxxxx, x xxxxxxx xx xxxxxx hodnotícího příslušného xxxxxx.
Xxxxxxxx xxxxxx přípravu xxxxxxxxxx x xxxxx z těchto xxxx, podle xxxx, xx xxxxxxx xxxxxxx:
x) |
xx xxx xxxxxx xx xxxxxxx xxxxxx; |
x) |
xx xxxxx xxxxxxxxx x xxxxxxx XXX. |
Xxxxxxxx xxxxxxxx stanovisko Xxxxxx xx 270 xxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 8
Účinné xxxxx, xxxxx xx xxxx xxxxxxxx
1. Xxx xxxxxxxx xxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxxxxxx prověří, xxx účinná xxxxx xxxxxxx xxxxxxx x xxxxxxxx xxxxxxxxx v čl. 10 xxxx. 1 xxxxxxxx (XX) č. 528/2012, x xxxx xxxxxx xxxxx xx xxxx xxxxxxxxxx.
2. Xxxx jsou xxxxxxx xxxxxx 66 x 67 nařízení (XX) x. 528/2012, xxxxx xxx xxxxxxxx xxxxxxxx xxx xxxxxxxxxx Xxxxxx, xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxx, xxxxx se xxxx xxxxxxxx, xxxxx maximálně 60 xxx; x xxxx xxxx mohou xxxxxxxxxx třetí xxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxx informací x xxxxxxxxxx xxxxxxxxx. Xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx zohlední x xxxxxxxxx fázi xxxxxxxx xxxxx stanoviska.
3. Xxxxx xx xxxxxx xxxxx xxxxxxxxx x xxxxxxx jedno x xxxxxxxx xxxxxxxxxxx v čl. 10 xxxx. 1 nařízení (XX) x. 528/2012, musí být xxxxxxxx xx xxxxx, xxxxx xx xx xxxxxxxx, x xxxxxxxx xxxxxxxx x xxxxxxx x xx. 89 odst. 1 xxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxxxx.
Xxxxxx 9
Rozhodnutí Komise
Po xxxxxxxx stanoviska agentury xxxxx čl. 7 xxxx. 2 Xxxxxx xxx xxxxxxxxxx xxxxxxxx xxxxxxxx xxxxx xxxxxxxxxx xxx přijetí xxxxx xx. 89 xxxx. 1, xxxx případně xxxxx xx. 28 xxxx. 1 xxxxxxxx (XX) x. 528/2012.
XXXXXXXX 3
ZMĚNY PRVKŮ XXXXXXXX PŘEZKUMU
Článek 10
Xxxxxxxxx xxxx xxxxxxxxx účastníků xx xxxxxxxx dohodě
1. Roli xxxxxxxxx xx xxxxx xx xxxxxxxx xxxxxx xxxx stávajícím účastníkem x xxxxxxxxxxxx účastníkem xxxxxxx xxxx sdílet xx předpokladu, xx xx xxxxxxxxxxx xxxxxxxx xxxxx xxxxxxxxx se xx xxxxxxx xxxxx xxxxxxxxxx xxxx uvedené xxxxxxxxxx xxxxxxxxxx.
2.&xxxx;&xxxx;&xxxx;Xxxxxxxx xxx xxxxx xxxxxx xxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx a stávající xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxxxxxx x xxxxxx 71 xxxxxxxx (XX) x. 528/2012 (xxxx xxx „xxxxxxxx“) a oznámení xxxx xxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxx k xxxxxxxx.
3.&xxxx;&xxxx;&xxxx;Xx xxxxxxxx oznámení splňujícího xxxxxxxxx podle odstavce 2 xxxxxxxx xxxxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxx týkající xx xxxxxxxxxx účastníka.
4. Osoba xxxxxxx xx&xxxx;xxxxx Xxxx, xxxxx xxxxxxxx xxxx xxxxxxxxx nebo xx xxxxxxxxx x xxxxxxxxxxx xxxxx tohoto xxxxxx, xx xxx xxxxx xxxxxx 95 xxxxxxxx (XX) x.&xxxx;528/2012 považována xx xxxxx, xxxxx xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx x xxxxxxxx x xxxxxxxxxxx.
Xxxxxx 11
Xxxxxxxxxx účastníků
1. Xx xx za to, xx xxxxxxxx odstoupil x účasti xx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxx xxxxxxxx, x xxxxxx xxxxxxxxx:
x) |
xxxxx xxxxxxxxxx agenturu xxxx xxxxxxxxx xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxx xxxxxx xxxxxxxxx; |
x) |
xxxxx nepředložil žádost xx lhůtě uvedené x xx. 3 xxxx. 2; |
x) |
pokud jeho xxxxxx byla xxxxxxxxx xxxxx xx. 4 odst. 1, xx. 4 xxxx. 4 nebo xx. 5 xxxx. 4; |
x) |
xxxxx xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxxxxxx uvedených v čl. 6 xxxx. 5; |
x) |
xxxxx xxxxx nezaplatil xxxxxxxx hodnotícímu příslušnému xxxxxx nebo agentuře. |
2. Odstoupení xx xxxxxxxx xx xxxxxxxxx xxxx, pokud x xxxx xxxxxxx xx datu, xxx xxxxxxxxx xxxxxxxxx orgán xxxxxxxxx žadateli xxxxxx xxxxxxxxxxx xxxxxx xxxxx xx. 6 xxxx. 4 tohoto xxxxxxxx.
Xxxxxx 12
Xxxxxxxx včasného xxxxxxxxxx
1. Xxxxx xx x xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx nikoli agentura, xxxxxxxxx xx xxxxxxxxx xxxxxxxxx orgán bez xxxxxxxxxx odkladu xxxxxxxxxxxxxxx xxxxxxxxx.
2. Xxxxx xx o xxxxxxx odstoupení informována xxxxxxxx, xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxx xx xxxxxxxxxx xxxxxxxxx.
3. Xxxxx x xxxxxxxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxx byla xxxx xxxxxxxxx xxx xxxxxxxx xxxxxxxxx xxxxx xxxxxxxx, xxxxxxxxx x xxx xxxxxxxx prostřednictvím rejstříku Xxxxxx.
Xxxxxx 13
Nová definice xxxxxxxxx xxxxx
1. Xxxxx xxxxxxxxx xxxxxxxxx xxxxxx látky xxxxxxxx xxxxxxx závěry xxxxxxxx xx xxxxx, xxx xxxx xxxxxxx x xxxxxxx XX, xxxxxxxxx xxxxxxxxx xxxxx xx xxxxxxxxxx x xxxxxxxx účastníkem xxxxxxx xxxxx xxxxxxxx xxxxx. Hodnotící příslušný xxxxx x xxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx v rejstříku aktualizuje xxxxxxxxx xxxxxxxx xx xxxxxxxx xxxxx.
Xxxxxx 14
Převzetí xxxx xxxxxxxxx
1. Xxxxxxxx zveřejní otevřenou xxxxx k převzetí xxxx xxxxxxxxx xxx xxxxxxxxx látky x xxxx xxxxxxxxx, xxxxx xxxxxxx xxxxx x xxxxxx případů:
x) |
xxxxx xxxxxxx účastníci podporující xxxxx kombinaci xxxxx x xxxx přípravku xxxx xxxxxxxxxx podle článku 11 x xxxxxx role xxxxxxxxx xxx xxxxx kombinaci xxxxxx xxxxxxx převzata; |
x) |
xx xxxxxxx xxxx xxxxxxxx xxxxx xxxxxx 13; v tomto xxxxxxx xx xxxxx xxxx xxxxx xx xxxxx, xx xxxxxx se xxxxxxxx xxxxxxxxx identita v příloze II, xxx xxxxxxx xxxx xxxxxxxx xxxxx. |
2. Xx xxxxxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx xxxxxxxx 1 xxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxx xxxxxx 17.
3. Xx xxxxxxxx xxxxxx xx xxxx xxxxxx tohoto nařízení x xxxxxxxx může xxxxxxxxx xxxxx oznámit xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx xx části 2 xxxxxxx XX xxxxx xxxxxx 17.
Xxxxxx 15
Xxxxxxxxx xxxxx x xxxx přípravku xxxxxxxxx pro zařazení xx xxxxxxxx xxxxxxxx
Xxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxx do oblasti xxxxxxxxxx xxxxxxxx (XX) x. 528/2012 x xx xxxxxx xx xxx, xxxxxxx xx xxxxxxxxx xxxxxx xxxxx, xxx xxxx xxxxxxxxx xxx xxxxxxxx do programu xxxxxxxx xxx xxxxx xxx xxxxxxxxx a xxxx xxxxxxxx xx xxxxxxx I xxxxxxxxx xxxxxxxx, tuto xxxxx xxxxxxxx nebo se x ní vyrábí, xx xxxxxxx xxxxx xxxxxxxxx xxx zařazení xx xxxxxxxx xxxxxxxx xxx xxxxxxxxx typ xxxxxxxxx xx xxxxxxx xxxxxxxxx x xxxxxx xxxxxx:
x) |
xxxxx xxxxxxxxx výrobek xx xxx xx xxxxxxxxx xx pokyny nebo xxxxxxx xxxxxxxxxx vydané Xxxxxx nebo xxxxxxxxxx xxxxxxx xxxxxxxxxx x xxxxxxx x xxxxxxx 26 xxxxxxxx 98/8/XX xxxx xxxxxxx 81 xxxxxxxx (XX) x. 528/2012, xxxxx na xxxxxxx xxxxxxxxxx opodstatněných xxxxxx xxxxx xxxxxxx xxxxxx xx xxxxxxxxxx x xxxxxxxxxxx, xx xxxxxxx xxx xxxxx x xxxxxxxxxx xxxxxxxx 98/8/XX xxxx nařízení (XX) x. 528/2012, xxxx xx xxx příslušný xxx přípravku xxxxxx x přípravků, xxx xxxxx byla xxxxxx xxxxx xxxxxxxx, a xxxxx xxxx xxxxxxx xxxxxx xx doporučení xxxxxxxx xxxxxxxxxxx v xxxxxxxxxx xxxxxxxx xxxxx xx. 3 odst. 3 xxxxxxxx (EU) x. 528/2012 xxxx x xxxxxx, xxxxxxxxx xxxxxxxx zveřejněných Xxxxxx; |
b) |
látka xxxxxxxxx odchylky xxx xxxxxxxxx a krmiva stanovené x xxxxxx 6 xxxxxxxx (XX) x. 1451/2007; |
x) |
biocidní xxxxxxxxx xxxxx podle nařízení (XX) č. 528/2012 x xxxxxxxxx xxxx přípravku, xxx xxxx bylo xxxxx xxxxxxxx 98/8/XX, x xxxxxxxx xxxxx xxxxxxxxxx těchto xxxx přípravků x xxxxxxxx xxxxx zařazenou xx xxxxxxxx xxxxxxxx xxx původní xxx xxxxxxxxx, xxx xxxxxx xxx xxxx. |
Xxxxxx 16
Xxxxxxxxxx x xxxxx xx oznámení
1. Prohlášení x xxxxx oznámit látku, xxxxx xx způsobilá xxx zařazení xx xxxxxxxx xxxxxxxx xxxxx článku 15, xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxx má zájem xxxxxxx xxxxxxxxx xxxxx x xxxx přípravku, xxxxxxx x xxxxxxxxxxxxx xxxxxxxx:
x) |
Xxxxxx xxxxxxxxxx dvanáct měsíců xx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx uvedených x xx. 15 xxxx. x); |
x) |
xxxxxxxx nejpozději 30. října 2015 x případech xxxxxxxxx x čl. 15 xxxx. x); |
x) |
Komisi xxxxxxxxxx 30. října 2015 x xxxxxxxxx xxxxxxxxx v čl. 15 xxxx. x). |
2. Xxxxxxxxxx xxxx obsahovat xxxxxxxxxx xxxxxxxxx látky x xxxx xxxxxxxxx. X xxxxxxxxx xxxxxxxxx x xx. 15 písm. x) musí xxxxxxxxxx xxxxxxxxx xxxxxxxxxxxx odůvodnění, x xxxx vyplývá, xx jsou splněny xxxxxxx podmínky v xxx xxxxxxx.
3. Xxxxx bylo xxxxxxxxxx učiněno x xxxxxxx xxxxxxxx x xx. 15 xxxx. x) xxxx x) x Xxxxxx dospěje xx xxxxxxxxxx x xxxxxxxxx státy x xxxxxx, že xxxxxxxx 6 není xxxxxxxxxx, x xxxxxxxx, xx xxxx xxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxx x xx. 15 xxxx. x), xxxxxxx o tom xxxxxxxx.
4. Xxxxx xxxx prohlášení xxxxxxx v případě xxxxxxxx x xx. 15 xxxx. b) xxxx xxxxx Xxxxxx xxxxxxxxxxx agenturu podle xxxxxxxx 3, xxxxxxxx xxxxxxxx xxxx informaci xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx. Pro účely xxxxxx xxxxxxxx se xxxxxxxxxx xxxxx čl. 3a xxxx. 3 třetího pododstavce xxxxxxxx (XX) x. 1451/2007 xxxxxxxx za xxxxxxxxxx xxxxx tohoto odstavce.
5. Xxxxxxxxx xxxxx, která má xxxxx xxxxxxx xxxxxxxxx xxxxx x xxxx xxxxxxxxx, xxx xxxx xxxxxx xxxxx xxxxxx 17 xx xxxxx xxxxxx xxx xxx xxxxxxxxxx xxxxx odstavce 4.
6. X xxxxxxxxx xxxxxxxxx x xx. 15 xxxx. x) x x) xx xxxxxxxxx látky x xxxx xxxxxxxxx považuje xx xxxxxxxxx xxxxxxxxxx x xxxx xxxxxxxxx k dalšímu xxxxxxxx, pokud xxxx xxxxxxx tyto xxxxxxxx:
x) |
příslušná xxxxxx látka je xxx xxxxxxxx xx xxxxxxxx xxxxxxxx; |
x) |
xxxxxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxx xxxxxxx xxxxx xxx xxxxxxxx xxxxxxx xxxxx, xxxxx jsou xxxxxxxx xxx xxxxxxxxx xxxx xxxxxxxxx; |
x) |
xxxxxxxx, který xxxxxxxxx xxxxxxxx xxxxxxxxxxx, xxxxx, že má xxxxx x xxxxxxx xxxx xxxxxxxxx látky x xxxx xxxxxxxxx. |
Xxxxxx 17
Xxxxxx oznámení
1. Xxxxxxxx xxxxx xx. 14 xxxx. 2 x 3 xxxx xx. 16 xxxx. 5 xx xxxxxxxxxxx xxxxxxxx prostřednictvím xxxxxxxxx.
2. Xxxxxxxx xxxx xxx xxxxxxxxxx xx formátu XXXXXX. Musí xxxxxxxxx xxxxx uvedené x xxxxxxx X.
3. Pokud xxxx x xxxxxxx XX pro xxxxxxxx xxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx xxxxx, xxxxxxxxx xxxxxxxxxxx xxxxxxxx x xxxxx xxx vybraného xxxxxxxxxxx orgánu, xxxxx xx xxxxxxxx v souladu x xxxxxxx 81 xxxxxxxx (EU) x. 528/2012, a poskytne xxxxxxx xxxxxxxxx dokládající, že příslušný xxxxx souhlasí s xxx, xx xxxxxxxxxxx xxxxxxx.
4. Xx xxxxxxxx xxxxxxxx x tom xxxxxxx xxxxxxxx Xxxxxx a xxxxxxxxxxxx xxxxxxxxx o poplatcích xxxxxxxxx podle xxxxxxxx (XX) x. 564/2013. Xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxx xx 30 xxx xx xxxxxxx xxxxxxx xxxxxxxxx, agentura xxxxxxxx xxxxxxx x xxxxxxx x xxx xxxxxxxxxxxx x Xxxxxx.
5. Xx xxxxxxxx xxxxxxxx xxxxxxxx do 30 xxx xxxxx, xxx xxxxxxxx xxxxxxxx xxxxxxxxxx uvedeným x xxxxxxxx 2. Pokud xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxx, poskytne agentura xxxxxxxxxxxx xxxxx x xxxxx 30 xxx, xxx své xxxxxxxx xxxxxxx xxxx opravil. Xx xxxxxxxx této 30xxxxx lhůty agentura xx 30 xxx xxx prohlásí, xx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx 2, xxxx xxxxxxxx zamítne, a xxx xxxxxxxxxx sdělí xxxxxxxxxxxx x Xxxxxx.
6. V xxxxxxx x xxxxxxx 77 xxxxxxxx (EU) x. 528/2012 xxxxx xxxxxxxxxxx xxxxxxxx podle xxxxxxxx 4 xxxx 5 xxxxx xxxxxxx xxxxxxxxxx.
7. Xxxxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xxxxxxxx 5:
a) |
x xxxxxxx, xx xxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 14 xxxx. 2 xxxx 3, xxxxxxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx týkající se xxxxxxxxxx xxxxxxxxx a xxxxxxxx xxxxxxxx xxxxx; |
x) |
x xxxxxxx, že oznámení xxxx xxxxxxxxxx xxxxx xx. 16 xxxx. 5, xxxxxxxx neprodleně xxxxxxxxx Xxxxxx, že xxxxxxxxxx xxxx xxxxxxxx. |
Xxxxxx 18
Zařazení xx xxxxxxxx xxxxxxxx
Pokud je xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxx xx xxxxxxxxx x xxxxxxx s čl. 16 xxxx. 6 xxxx xxxxx xxxxxxxx xxxxxxxxx Xxxxxx x xxxxxxxx xxxxxxxxx x xxxxxxx x xx. 17 xxxx. 7 písm. b), xxxxxx Xxxxxx kombinaci látky x xxxx xxxxxxxxx xx xxxxxxxx xxxxxxxx.
Xxxxxx 19
Xxxxxxxxx o xxxxxxx, xxxxx xxxxxx xxxxxx podporovány x xxxxx programu xxxxxxxx
Pokud xxxxxx xx xxxxx stanovené x xx. 16 xxxx. 5 obdrženo xxxxx oznámení nebo xxxxx byla xxxxxxxx xxxxxxx xx xxxxxxxx xxxxxx přijata x xxxxxxxx xxxxxxxxx agenturou xxxxx xx. 17 odst. 4 nebo 5, xxxxxxxx o tom xxxxxxxxx členské xxxxx xxxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxx xxxx xxxxxxxxx elektronickou xxxxxx.
Xxxxxx 20
Rozhodnutí Xxxxxx x látkách, xxxxx xxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxx xxxxxxxx
Xxxxxx xxxxxxxx xxxxx xxxxxxxxxx o neschválení xxxxx xx. 89 xxxx. 1 xxxxxxx xxxxxxxxxxx xxxxxxxx (XX) x. 528/2012 v těchto xxxxxxxxx:
x) |
xxxxx xxxxxxxx xxxxxxxxx Xxxxxx o včasném xxxxxxxxxx xxxxxxxxx xxxxx xx. 12 xxxx. 3 tohoto xxxxxxxx; |
b) |
xxxxx xxxxx xxxxx xxxxxxxx xxxxxxxx xx xxxxxxx xxxxxxxxxxx x xx. 14 xxxx. 2 nebo 3 xxxxxx xxxxxxxx xxxx pokud xxxx xxxxxxxx předloženo x xxxxxxxxx xxxxx čl. 17 odst. 4 xxxx 5; |
c) |
xxxxx xxxx xxxxxxxx předloženo ve lhůtě xxxxxxxxx x xx. 14 xxxx. 2 xxxx 3 xxxxxx xxxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxxxx čl. 17 xxxx. 5 xxxxxx nařízení, xxx identita xxxxx x xxxxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx identity x xxxxxxx XX tohoto nařízení. |
X xxxxxxx xxxxxxxx x xxxxxx xxxxxxxxxxx xxxx. x) xx xxxxx rozhodnutí o xxxxxxxxxxx xxxxxxxx xx xxxxxx xxxxx, xx xxxxxx xx xxxxxxxx stávající xxxxxxxx x xxxxxxx XX xxxxxx xxxxxxxx, xxxxx xxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx x schválení.
XXXXXXXX 4
PŘECHODNÁ XXXXXXXX
Xxxxxx 21
Xxxxxxxxx xxxxxxxx pro xxxxx xxxxxxx x&xxxx;xxxxxx&xxxx;15
1.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx pokračovat x&xxxx;xxxxxxxxxxx svého xxxxxxxxxxx xxxxxxx nebo praxe xxxxxxxx xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx přípravku, který xxxxxxx xx xxxxxxxxx xxxxxx látky xxxxxxx x xx. 15 xxxx. b) x x), xxxx xxxxx xxxxxxxx xxxx z xx vzniká. V xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx přípravek nadále xxxxxxx xx&xxxx;xxx s účinkem xx&xxxx;24 xxxxxx xx xxxx vstupu xxxxxx xxxxxxxx x&xxxx;xxxxxxxx; |
x) |
xxxxxxxxx zásoby xxxxxxxxxx xxxxxxxxx xxxxx xxx dále xxxxxxxxx xx&xxxx;30 měsíců po xxx vstupu tohoto xxxxxxxx x&xxxx;xxxxxxxx. |
2.&xxxx;&xxxx;&xxxx;Xxxxxxx xxxx xxxx xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxx dodávání xx&xxxx;xxx x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx sestává xx xxxxxxxxx účinné xxxxx xxxxxxx x xx. 15 xxxx. x), xxxx xxxxx xxxxxxxx xxxx x xx xxxxxx. V xxxxxx xxxxxxxxx:
x) |
xxxxx xxx xxxxxxxx xxxxxxxxx xxxxxx xxxxxxx na trh s účinkem xx&xxxx;24 měsíců xx xx x xxxx xxxxxxxxx xxxxxxxx, která xxxxxxx xxxxxxx:
|
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx xxxx xxxxxxxxx xx&xxxx;30 xxxxxx xx xx x xxxx xxxxxxxxx xxxxxxxx, xxxxx xxxxxxx xxxxxxx:
|
3.&xxxx;&xxxx;&xxxx;Xxxxxxx stát může xxxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxx xxxxxxxxxxx xxxxxxx nebo xxxxx dodávání na trh x&xxxx;xxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxxx xxxxxxx ze xxxxxxxxx xxxxxx látky xxxxxxxxxx xxxxxxxxx xxxxx xx. 16 xxxx. 4 xxx příslušný xxx xxxxxxx, xxxx xxxxx obsahuje xxxx x ní xxxxxx. X xxxxxx xxxxxxxxx:
x) |
xxxxx xxx biocidní xxxxxxxxx xxxxxx dodáván na trh x&xxxx;xxxxxxx xx&xxxx;xxxxxxxx xxxxxx xx xxxx, xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxx 19 x |
x) |
xxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxx xxx xxxx využívány xx&xxxx;xxxxxxxx měsíců po xxxx xxxxxxxxx zveřejnění. |
Xxxxxx 22
Xxxxxxxx xxxxxxx
1. Xxxx xx xxxxxx xx. 55 xxxx. 1 xxxxxxxx (EU) x. 528/2012, xx xxxxxxxx xxxxxx xx xxxx rozhodnutí o neschválení xxxxxxxxx xxxxxx látky, xxxxx členský stát xxxxxxxx tuto xxxxxxxxx xxxxxxx látku xx xxxxxxxxx z důvodů xxxxxxxxx x xx. 5 xxxx. 2 xxxxxx xxxxxxxxxxx xxxx. b) xxxx x) xxxxxxxx (EU) x. 528/2012, tento členský xxxx xxxx předložit Xxxxxx odůvodněnou žádost x xxxxxxxx xx xx. 89 xxxx. 2 xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx.
2. Xxxxxxxx členský xxxx xxxxxxxx odůvodněnou žádost xxxxxxxx xxxxxxxxxxxxxxx rejstříku. Xxxxx xxxxxx xxxxxxxx xxxxxxx xxxxxxxxx, xxxxxxxx xxxxxxx xxxx xxxx xxxxxxx předložit xxxxxxxxx xxxxx.
3. Xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxxxx nedůvěrnou xxxxx xxxxxxxxxxxxxx prostředky. Xxxxxxx státy xxxx xxxx xxxxx mohou xxxxx připomínky xx xxxxx 60 xxx xx xxxxxxxxxx.
4. Xx xxxxxxx obdržených xxxxxxxxxx xxxx Xxxxxx xxxxxxx odchylku xx xx. 89 xxxx. 2 druhého xxxxxxxxxxx xxxxxxxx (EU) č. 528/2012, xxxxx xxxxxx xxxxxx xxxxxxxx přípravky, jež xxxxxxxxx z této xxxxx, xxxxxxxx xx xxxx z ní xxxxxxxx, na xxx xxxxxxxxxx xxxxxxxxx xxxxx x xxxxxxxx je v daném xxxxxxxx xxxxx v souladu x xxxxxxxxxxxxxx xxxxxxxx xxxxxxxx x x xxxxxxxx xxxxxxxx odstavce 5 a veškerých xxxxxxx xxxxxxxx xxxxxxxxx Xxxxxx.
5. Členský xxxx, xxxxx xx xxxxxxxx xxxxxxxx:
x) |
zajistí, že další xxxxxxxxx xxxx xxxxxxx xx xxxxxx xxxxxxx a xxxxxxx dobu, xxx xxxx xxxxxx xxxxxxxx xxxxxxxx 1; |
x) |
xxxxxx xxxxxx xxxxxxxx xx xxxxxxxx rizik, aby xxxxxxxx xxxxxxxxxxxx expozice xxxxxxx, xxxxxx xxxx xxxxxxxxx xxxxxxxxx; |
x) |
xxxxxxx, aby xx hledala xxxxxxxxxxxx xxxxxx xxxx xxx xxxx xxxx před xxxxxxxxx platnosti xxxxxxxx xxxxxxxxxx xxxxxx x xxxxxxxxx xxxxxx xxxxx v souladu xxxxxxx 7 xxxxxxxx (XX) č. 528/2012. |
KAPITOLA 5
XXXXXXXXX XXXXXXXXXX
Xxxxxx 23
Xxxxxxx
Xxxxxxx se nařízení (XX) č. 1451/2007.
Xxxxxx xx zrušené nařízení xx považují za xxxxxx xx toto xxxxxxxx.
Xxxxxx 24
Vstup x xxxxxxxx
Xxxx nařízení xxxxxxxx x platnost xxxxxxxx xxxx po vyhlášení x Úředním xxxxxxxx Xxxxxxxx unie.
Xxxx nařízení je xxxxxxx x xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx všech xxxxxxxxx xxxxxxx.
X Xxxxxxx xxx 4. xxxxx 2014.
Xx Xxxxxx
xxxxxxxx
Xxxx Xxxxxx XXXXXXX
(1) Úř. věst. X 167, 27.6.2012, x. 1.
(2) Nařízení Komise (XX) x. 1451/2007 ze xxx 4. prosince 2007 x xxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxx xxxxxxxx uvedeného v xx. 16 odst. 2 xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady 98/8/XX x uvádění xxxxxxxxxx xxxxxxxxx xx xxx (Xx. xxxx. X 325, 11.12.2007, x. 3).
(3) Směrnice Xxxxxxxxxx xxxxxxxxxx x Xxxx 98/8/XX xx dne 16. xxxxx 1998 x xxxxxxx biocidních xxxxxxxxx xx xxx (Úř. xxxx. X 123, 24.4.1998, s. 1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxx dvora (xxxxxxx senátu) xx xxx 1. xxxxxx 2012 (žádost x xxxxxxxxxx x xxxxxxxxx xxxxxx: Xxxxxxxxxxx Xxxxxxx – Xxxxxxx) – Xöxx GmbH xxxxx Xxxxx XxxX (uvádění xxxxxxxxxx xxxxxxxxx na xxx – xxxxxxxx 98/8/XX – čl. 2 odst. 1 xxxx. a) – xxxxx „biocidní xxxxxxxxx“ – xxxxxxxxx, který xxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxx, xxxx je xxxx, odpuzuje xxxx xxxxxxxxxxx), X-420/10.
(5)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;88/2014 xx xxx 31.&xxxx;xxxxx 2014, xxxxxx xx stanoví xxxxxx pro xxxxx xxxxxxx X&xxxx;xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 x&xxxx;xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx používání (Xx. xxxx. L 32, 1.2.2014, x. 3).
(6)&xxxx;&xxxx;Xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx xxxxx a xxxxx, x xxxxx x xxxxxxx xxxxxxx 67/548/XXX x 1999/45/ES a x změně nařízení (XX) x. 1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, s. 1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Komise (XX) x.&xxxx;564/2013 ze xxx 18.&xxxx;xxxxxx 2013 x&xxxx;xxxxxxxxxx a platbách splatných Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx podle xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (XX) č. 528/2012 x&xxxx;xxxxxxxx biocidních xxxxxxxxx xx xxx a jejich xxxxxxxxx (Xx.&xxxx;xxxx.&xxxx;X 167, 19.6.2013, s. 17).
(8)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 ze xxx 18. xxxxxxxx 2006 x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx a xxxxxxxxx xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx chemické xxxxx, x xxxxx xxxxxxxx 1999/45/ES a x xxxxxxx xxxxxxxx Xxxx (XXX) č. 793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x xxxxxxx Komise 91/155/EHS, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, x. 1).
XXXXXXX X
Xxxxxxxxx požadované xxx xxxxxxxx podle xxxxxx 17
Oznámení podle xxxxxx 17 obsahuje xxxx xxxxxxxxx:
1) |
důkaz, že látka xx stávající xxxxxxx xxxxxx xx xxxxxx čl. 3 xxxx. 1 xxxx. x) xxxxxxxx (XX) x. 528/2012; |
2) |
xxxxx x xxxx/xxxxxx xxxxxxxxx, xx xxxxx/x se oznámení xxxxxxxx; |
3) |
xxxxxxxxx x xxxxx studiích, xxxxx xxxx zadány xxx xxxxx xxxxxxx x xxxxxxxxx xx xxxxxxxx xx xxxxxxx X xxxxxxxx (EU) x. 528/2012, jakož i očekávané xxxxx xxxxxx dokončení; |
4) |
xxxxxxxxx xxxxxxx x xxxxxxxx
|
5) |
pokud xxxx xxxx xxxxxxxx xxxxxxx x xxxxxxx xxxxxxxx x xx. 15 písm. x), xxxxx, že látka xxxx xx xxxx jako xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxxxxx xx xxxxxxxxxxx typu xxxxxxxxx x xxx xxxxxxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxxxxxx xx xxxxxxxx xxxxxxx. |
XXXXXXX II
XXXXXXXXX XXXXX X XXXX PŘÍPRAVKU XXXXXXXX XX XXXXXXXX XXXXXXXX XXX 4. XXXXX 2014
XXXX 1
Xxxxxxxxx xxxxxx látky x xxxx xxxxxxxxx podporované xx xxx 4. xxxxx 2014, x xxxxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxxxxx xxx xxxx, xxxxx xxxx xxxxxxxx uvedeny x xxxxxxxxx 1017 x 1019.
Xxxxx xxxxxxx |
Xxxxx látky |
Xxxxxxx xxxx xxxxxxxxx |
Xxxxx XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1 |
xxxxxxxxxxx |
XX |
200-001-8 |
50-00-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
6 |
5-{[2-(2-butoxyethoxy)ethoxy]methyl}-6- xxxxxx-1,3-xxxxxxxxxxx (xxxxxxxxxxxxxxxx/XXX) |
XX |
200-076-7 |
51-03-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
9 |
xxxxxxxx |
XX |
200-143-0 |
52-51-7 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
|
|
|
|
|
x |
29 |
xxxxxxxxxxx |
XX |
200-431-6 |
59-50-7 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
36 |
xxxxxxx |
XX |
200-578-6 |
64-17-5 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
37 |
xxxxxxxx mravenčí |
XX |
200-579-1 |
64-18-6 |
|
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
40 |
xxxxxx-2-xx |
XX |
200-661-7 |
67-63-0 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43 |
xxxxxxxx salicylová |
NL |
200-712-3 |
69-72-7 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
propan-1-ol |
DE |
200-746-9 |
71-23-8 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
xxxxxxxxxxx |
X |
200-849-9 |
75-21-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60 |
kyselina xxxxxxxxx |
XX |
201-069-1 |
77-92-9 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
69 |
xxxxxxxxx kyselina/2-hydroxyethanová kyselina |
XX |
201-180-5 |
79-14-1 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70 |
xxxxxxxx xxxxxxxxxxxx |
XX |
201-186-8 |
79-21-0 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
71 |
X-(+)-xxxxxx xxxxxxxx |
XX |
201-196-2 |
79-33-4 |
|
x |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
79 |
2-isopropenyl-8,9-dimethoxy-1,2,6,6a,12,12a-hexahydrochromeno[3,4-b]furo[2,3-h]chromen-6-on (xxxxxxx) |
XX |
201-501-9 |
83-79-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
85 |
xxxxxxxxx |
UK |
201-782-8 |
87-90-1 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
92 |
bifenyl-2-ol |
XX |
201-993-5 |
90-43-7 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
113 |
xxxxxxxxxxxxx/3-xxxxxxxxx-2-xxxx (xxxxxxxxxxxxx) |
XX |
203-213-9 |
104-55-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 |
xxxxxxxx |
XX |
203-377-1 |
106-24-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
122 |
xxxxxxx |
XX |
203-474-9 |
107-22-2 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
xxxx-2,4-xxxxxxx xxxxxxxx (xxxxxxxx xxxxxxx) |
XX |
203-768-7 |
110-44-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
136 |
xxxxxxxx (xxxxxxxxxxxxx) |
XX |
203-856-5 |
111-30-8 |
|
x |
x |
x |
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
154 |
xxxxxxxxx |
N |
204-385-8 |
120-32-1 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
171 |
2-xxxxxxxxxxx-1-xx |
XX |
204-589-7 |
122-99-6 |
x |
x |
|
x |
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
172 |
xxxxxxxxxxxxxxx-xxxxxxx/1-xxxxxxxxxxxxxxxx-1-xxx-xxxxxxx |
UK |
204-593-9 |
123-03-5 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
179 |
xxxx xxxxxxxx |
FR |
204-696-9 |
124-38-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
180 |
(xxxxxxx-xxxxxxxxx) – xxxxxxx-xxxxxxxxxxxxxxx |
XX |
204-708-2 |
124-65-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
185 |
tosylchloramid, sodná xxx (xxxxx sůl xxxxxxxxxxxxxxx – chloramin X) – (N-chlor-4-methylbenzen-1-sulfonamid |
XX |
204-854-7 |
127-65-1 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
187 |
xxxxxx-xxxxxxxxxxxxxxxxxxxxxx |
XX |
204-875-1 |
128-03-0 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
188 |
natrium-dimethyldithiokarbamát |
UK |
204-876-7 |
128-04-1 |
|
|
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
195 |
natrium-bifenyl-2-olát |
ES |
205-055-6 |
132-27-4 |
x |
x |
x |
x |
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
198 |
X-[(xxxxxxxxxxxxxx)xxxxxxxx]xxxxxxxx (xxxxxx) |
XX |
205-088-6 |
133-07-3 |
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
206 |
xxxxxx |
XX |
205-286-2 |
137-26-8 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
210 |
xxxxxx-xxxxxxx |
XX |
205-293-0 |
137-42-8 |
|
|
|
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
227 |
2-(xxxxxxx-4-xx)xxxxxxxxxxxx (xxxxxxxxxxxx) |
ES |
205-725-8 |
148-79-8 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
235 |
xxxxxx |
XX |
206-354-4 |
330-54-1 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
239 |
xxxxxxxxxxxxx |
XX |
206-992-3 |
420-04-2 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
253 |
tetrahydro-3,5-dimethyl-1,3,5-thiadiazin-2-thion (xxxxxxx) |
XX |
208-576-7 |
533-74-4 |
|
|
|
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
279 |
N-[(dichlorfluormethyl)sulfanyl]-N′,N′-dimethyl-N-(4-methylfenyl)sulfonamid (xxxxxxxxxxxx) |
XX |
211-986-9 |
731-27-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
283 |
xxxxxxxxx |
XX |
212-950-5 |
886-50-0 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
288 |
X-[(xxxxxxxxxxxxxxxxxx)xxxxxxxx]-X-xxxxx-X′,X′-xxxxxxxxxxxxxxxx (xxxxxxxxxxxxx) |
UK |
214-118-7 |
1085-98-9 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
x |
|
289 |
thiokyanatan xxxxx |
FR |
214-183-1 |
1111-67-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
292 |
[(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl]-trans-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (x-xxxxx-xxxxxxxxxxxx) |
XX |
214-619-0 |
1166-46-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
958 |
xxxxxxxx xxxxxxxx/xxxxxxxxxxx vápno/hašené xxxxx |
XX |
215-137-3 |
1305-62-0 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
959 |
xxxx vápenatý/vápno/pálené xxxxx/xxxxxxxx xxxxx |
XX |
215-138-9 |
1305-78-8 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
306 |
xxxx měďný |
XX |
215-270-7 |
1317-39-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
315 |
butan-2-on-peroxid |
XX |
215-661-2 |
1338-23-4 |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
321 |
monolinuron |
XX |
217-129-5 |
1746-81-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330 |
N-(3-aminopropyl)-N-dodecylpropan-1,3-diamin (xxxxxx) |
PT |
219-145-8 |
2372-82-9 |
|
x |
x |
x |
|
x |
|
x |
|
|
x |
x |
x |
|
|
|
|
|
336 |
X,X′-xxxxxxxx-2,2′-xxxxxxxxxxxxxxxxxxxxxx (XXXXX) |
XX |
219-768-5 |
2527-58-4 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
339 |
1,2-xxxxxxxxxxxxxxx-3(2X)-xx (XXX) |
ES |
220-120-9 |
2634-33-5 |
|
x |
|
|
|
x |
|
|
x |
|
x |
x |
x |
|
|
|
|
|
341 |
2-methyltetrahydroisothiazol-3(2H)-on (XXX) |
XX |
220-239-6 |
2682-20-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
346 |
xxxxxxx-xxxxxxxxxxxxxxxxxx xxxxxxxx |
XX |
220-767-7 |
51580-86-0 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
345 |
xxxxxxx-xxxxxxxxxxxxxxxxxx |
XX |
220-767-7 |
2893-78-9 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
348 |
xxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxx-xxxxxx (XXX) |
XX |
221-106-5 |
3006-10-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
354 |
triklosan |
XX |
222-182-2 |
3380-34-5 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 |
(xxxxxxxxxxxx)xxxxxxxxxx (xxxxxxx xxxxxxxx xxxxxxxxxxxxxx a xxxxxxxxxxxxxxxx (EGForm)) |
XX |
222-720-6 |
3586-55-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
365 |
pyridin-2-thiol-1-oxid, xxxxx xxx (xxxxxxxxx xxxxx) |
XX |
223-296-5 |
3811-73-2 |
|
x |
x |
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
368 |
1-(3-xxxxxxxxxx)-3,5,7-xxxxxx-1-xxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
223-805-0 |
4080-31-3 |
|
|
|
|
|
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
377 |
1,3,5-xxxx(2-xxxxxxxxxxxx)xxxxxxxxx-1,3,5-xxxxxxx (XXX) |
XX |
225-208-0 |
4719-04-4 |
|
|
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
382 |
1,3,4,6-xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxxxxxxxxx[4,5-x]xxxxxxxx-2,5-xxxx (XXXX) |
ES |
226-408-0 |
5395-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
387 |
xxxxxxxxxxxxxxxxx (XXX) |
XX |
227-062-3 |
5625-90-1 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
392 |
xxxxxxxx-xxxxxxxxxxxx |
XX |
228-652-3 |
6317-18-6 |
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
393 |
1,3-xxx(xxxxxxxxxxxxx)-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (XXXXX) |
XX |
229-222-8 |
6440-58-0 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
397 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) |
XX |
230-525-2 |
7173-51-5 |
x |
x |
x |
x |
|
x |
|
x |
|
x |
x |
x |
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
x |
|
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
403 |
xxx |
FR |
231-159-6 |
7440-50-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
405 |
xxxx xxxxxxxx |
XX |
231-195-2 |
7446-09-5 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
424 |
xxxxxx xxxxx |
NL |
231-599-9 |
7647-15-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
432 |
xxxxxxxx xxxxx |
IT |
231-668-3 |
7681-52-9 |
x |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
434 |
xxxxxxxxxxxx |
DE |
231-711-6 |
7696-12-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
439 |
xxxxxxx xxxxxx |
XX |
231-765-0 |
7722-84-1 |
x |
x |
x |
x |
x |
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
444 |
7x-xxxxxxxxxxxx-1X,3X,5X-xxxxxxx[3,4-x]xxxxxx (XXXX) |
PL |
231-810-4 |
7747-35-5 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
450 |
xxxxxxxx xxxxxxxx |
SE |
231-853-9 |
7761-88-8 |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
453 |
peroxodisíran xxxxx |
XX |
231-892-1 |
7775-27-1 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455 |
xxxxxxxx xxxxxxxx |
XX |
231-908-7 |
7778-54-3 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
457 |
xxxxx |
XX |
231-959-5 |
7782-50-5 |
|
x |
|
|
x |
|
|
|
|
|
x |
|
|
|
|
|
|
|
458 |
xxxxx xxxxxx |
XX |
231-984-1 |
7783-20-2 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
473 |
xxxxxxxxxx x xxxxxxxxxxx |
XX |
232-319-8 |
8003-34-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
491 |
oxid xxxxxxxxxx |
PT |
233-162-8 |
10049-04-4 |
|
x |
x |
x |
x |
|
|
|
|
|
x |
x |
|
|
|
|
|
|
494 |
2,2-dibrom-2-kyanacetamid (XXXXX) |
XX |
233-539-7 |
10222-01-2 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
501 |
xxxxxxxxxxx |
XX |
234-232-0 |
10605-21-7 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
|
|
|
|
|
|
515 |
xxxxxx xxxxxx |
SE |
235-183-8 |
12124-97-9 |
|
|
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
522 |
zink-1-oxo-1λ5-pyridin-2-thiolát |
XX |
236-671-3 |
13463-41-7 |
|
x |
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
x |
|
524 |
xxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxx |
XX |
237-030-0 |
13590-97-1 |
|
|
|
|
|
x |
|
|
|
|
x |
|
|
|
|
|
|
|
526 |
xxxxxx-xxxxxxx-2-xxxx |
XX |
237-243-9 |
13707-65-8 |
|
|
|
|
|
x |
|
|
x |
x |
|
|
x |
|
|
|
|
|
529 |
xxxxxxxxxxxxxxx |
XX |
237-601-4 |
13863-41-7 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
531 |
(benzyloxy)methanol |
XX |
238-588-8 |
14548-60-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
534 |
xxx(1-xxxxxxxxxxxxxx-2(1X)-xxxxxxxx-X,X)xxxxxxx xxxxxxx (xxxxxxxxx xxxx) |
XX |
238-984-0 |
14915-37-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
541 |
xxxxxxx-4-xxxxx-3-xxxxxxxxxxxxx |
XX |
239-825-8 |
15733-22-9 |
x |
x |
x |
|
|
x |
|
|
x |
|
|
|
x |
|
|
|
|
|
550 |
5,5′-xxx(4-xxxxxxxxxx)-1,1′-(xxxxx-1,6-xxxx)xxx(xxxxxxxx)-xxx(x-xxxxxxxx) (XXXX) |
PT |
242-354-0 |
18472-51-0 |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
|
|
|
|
|
|
559 |
[(benzothiazol-2-yl)sulfanyl]methyl-thiokyanát (XXXXX) |
X |
244-445-0 |
21564-17-0 |
|
|
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
562 |
[2-xxxxxx-4-xxx-3-(xxxx-2-xx-1-xx)xxxxxxxxx-2-xx-1-xx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
245-387-9 |
23031-36-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
563 |
kalium-(E,E)-hexa-2,4-dienoát (sorbát xxxxxxxx) |
XX |
246-376-1 |
24634-61-5 |
|
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
566 |
α, α′,α′′-xxxxxxxxxxxxxxxxxx-1,3,5-xxxxxxx-1,3,5-xxxxxxxxxx (XXX) |
AT |
246-764-0 |
25254-50-6 |
|
x |
|
|
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
571 |
2-oktyltetrahydroisothiazol-3-on (XXX) |
XX |
247-761-7 |
26530-20-1 |
|
|
|
|
|
x |
x |
|
x |
x |
x |
|
x |
|
|
|
|
|
577 |
xxxxxxxx(xxxxxxxxx)[3-(xxxxxxxxxxxxxxx)xxxxxx]xxxxxxx-xxxxxxx |
XX |
248-595-8 |
27668-52-6 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
578 |
X2-xxxx-xxxxx-X4-xxxxxxxxxxx-6-(xxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxx) |
XX |
248-872-3 |
28159-98-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
588 |
xxxxxxxxx-5,5-xxxxxxxxxxxxxxxxxxxx-2,4-xxxx (BCDMH/bromchlordimethylhydantoin) |
XX |
251-171-5 |
32718-18-6 |
|
x |
|
|
|
|
|
|
|
|
x |
x |
|
|
|
|
|
|
590 |
3-(4-isopropylfenyl)-1,1-dimethylmočovina/isoproturon |
XX |
251-835-4 |
34123-59-6 |
|
|
|
|
|
|
x |
|
|
x |
|
|
|
|
|
|
|
|
597 |
1-[2-(xxxxxxxx)-2-(2,4-xxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxx) |
XX |
252-615-0 |
35554-44-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
599 |
S-[(6-chlor-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl]-O,O-dimethyl-fosforothioát (xxxxxxxxxxx) |
XX |
252-626-0 |
35575-96-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
600 |
2-xxxx-2-(xxxxxxxxxx)xxxxxxxxxxxxxx (XXXXX) |
XX |
252-681-0 |
35691-65-7 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
961 |
xxxx vápenato-hořečnatý/dolomitické xxxxx |
XX |
253-425-0 |
37247-91-9 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
962 |
xxxxxxxx xxxxxxxx-xxxxxxxxx/xxxxxxxxxxx xxxxxxxxxxx xxxxx |
XX |
254-454-1 |
39445-23-3 |
|
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
606 |
[(3-xxxxxxxxxxx)xxxxxxxxxx]-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxxxxxxxxx) |
XX |
254-484-5 |
39515-40-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
608 |
dimethyl(tetradecyl)[3-(trimethoxysilyl)propyl]amonium-chlorid |
XX |
255-451-8 |
41591-87-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
609 |
cis- x xxxxx-x-xxxxxxx-3,8-xxxx (směs) (xxxxxxxxxx) |
XX |
255-953-7 |
42822-86-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
614 |
(XX)-α-xxxxx-3-xxxxxxxxxxxx-(1XX)-xxx,xxxxx-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxxxx) |
XX |
257-842-9 |
52315-07-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (permethrin) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
618 |
[1-ethynyl-2-methylpent-2-en-1-yl]-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyklopropan-1-karboxylát (xxxxxxxxxx) |
XX |
259-154-4 |
54406-48-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
619 |
3-xxxxxxx-2-xx-1-xx-X-xxxxxxxxxxxxx (XXXX) |
XX |
259-627-5 |
55406-53-6 |
|
|
|
|
|
|
x |
|
x |
x |
|
|
x |
|
|
|
|
|
620 |
xxxxxxxx(xxxxxxxxxxxxx)xxxxxxxxx-xxxxxx (2:1) (XXXX) |
XX |
259-709-0 |
55566-30-8 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
|
|
|
|
|
|
628 |
(±)-1-{[2-(2,4-xxxxxxxxxxxx)-4-xxxxxx- 1,3-xxxxxxxx-2-xx]xxxxxx}-1X-1,2,4-xxxxxxx (xxxxxxxxxxxx) |
FI |
262-104-4 |
60207-90-1 |
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
635 |
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx xxxxx (XXXXX/XXXX) |
IT |
263-038-9 |
61789-18-2 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
648 |
4,5-dichlor-2-oktylisothiazol-3(2H)-on (4,5-xxxxxxx- 2-xxxxx-2X-xxxxxxxxxx-3-xx (XXXXX)) |
X |
264-843-8 |
64359-81-5 |
|
|
|
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
|
649 |
1-(2-xxxxxxxxxxx)-3-[(xxxxxxxxxxxxxxx)xxxxx]xxxxxxxx (xxxxxxxxxxx) |
XX |
264-980-3 |
64628-44-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
656 |
bis(5-methyloxazolidin-3-yl)methan (xxxxxxxxxx/XXX) |
XX |
266-235-8 |
66204-44-2 |
|
x |
|
|
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
657 |
6-(xxxxxxxxxxxxxxxx)-1,3,5-xxxxxxx-2,4-xxxxxx (xxxxxxxxx) |
XX |
266-257-8 |
66215-27-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
666 |
[(3-fenoxy-4-fluorfenyl)kyanmethyl]-3-(2,2-dichlorvinyl)-2,2-dimethylcyklopropan-1-karboxylát (cyfluthrin) |
DE |
269-855-7 |
68359-37-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
667 |
alkyl(C12-18)dimethylbenzylammoniumchlorid (XXXXX (X12-18)) |
XX |
269-919-4 |
68391-01-5 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
671 |
xxxxx(X12-16)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (ADBAC/BKC (X12-X16)) |
XX |
270-325-2 |
68424-85-1 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
673 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx (XXXX) (X8-10) |
IT |
270-331-5 |
68424-95-3 |
x |
x |
x |
x |
|
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
690 |
alkyl(C12-C18)benzyl(dimethyl)amoniové xxxx 1,1-xxxxx-1λ-1,2-xxxxxxxxxxxxxxx-3(2X)-xxx (ADBAS) |
XX |
273-545-7 |
68989-01-5 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691 |
xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxx |
XX |
274-357-8 |
70161-44-3 |
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
PT |
274-687-2 |
70592-80-2 |
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
693 |
xxx(xxxxxxxxxxx)-xxx(xxxxx) xxxxxxxxxxxxx |
XX |
274-778-7 |
70693-62-8 |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
701 |
xxxxxxxxx-xxxxxxxxxxxxxxxx hexahydrát (XXXX) |
XX |
279-013-0 |
84665-66-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1015 |
xxxxxxx, Xxxxxxxxxxx indica, výtažek |
DE |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
724 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXX (X12-X14)) |
XX |
287-089-1 |
85409-22-9 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
725 |
xxxxx(X12-X14)xxxxxxxxxxxxxxxxxxxxxxxxxx (XXXXXX (X12-X14)) |
XX |
287-090-7 |
85409-23-0 |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
731 |
xxxxxxxxx stračkolistá, Xxxxxxxxxxxxx xxxxxxxxxxxxxxxx, xxxxxxx |
XX |
289-699-3 |
89997-63-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
744 |
xxxxxxxxx xxxxxx, Xxxxxxxxx xxxxxxx, výtažek/levandulový xxxx |
XX |
294-470-6 |
91722-69-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
776 |
1-[3,5-xxxxxxx-4-(1,1,2,2-xxxxxxxxxxxxxxxx)xxxxx]-3-(2,6-xxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxxxxxx) |
PT |
401-400-1 |
86479-06-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
779 |
xxxxxxx produkty xxxxxxxxx xxxxxxxx a X-xxxxx(X12-X14)xxxxxx-1,2-xxxxxxx (glukoprotamin) |
DE |
403-950-8 |
164907-72-6 |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
785 |
6-ftalimidoperoxyhexanová xxxxxxxx (XXX) |
XX |
410-850-8 |
128275-31-0 |
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
791 |
2-xxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx (XXXX) |
XX |
420-590-7 |
4299-07-4 |
|
|
|
|
|
x |
x |
|
x |
x |
|
|
x |
|
|
|
|
|
792 |
komplex xxxxxxxxxxxxxxxxxxx (XXXX) |
XX |
420-970-2 |
92047-76-2 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
811 |
xxxxxxxxxxxxxxxxxxx xxxxxxxx-xxxxx-xxxxxxxxxxx |
XX |
422-570-3 |
265647-11-8 |
x |
x |
|
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
794 |
xxx-xxxxx-2,2-(2-xxxxxxxxxxxx)xxxxxxxxx-1-xxxxxxxxxx (xxxxxxxx) |
DK |
423-210-8 |
119515-38-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
797 |
1-((Z)-3-chlorallyl)-3,5,7-triaza-1-azoniaadamantanchlorid (xxx-XXXX) |
XX |
426-020-3 |
51229-78-8 |
|
|
|
|
|
x |
|
|
|
|
|
|
x |
|
|
|
|
|
800 |
{[2,5-xxxxx-3-(xxxx-2-xx-1-xx)xxxxxxxxxxxx-1-xx]xxxxxx}-2,2-xxxxxxxx-3- (2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx- 1-karboxylát (xxxx stereoisomerů) (xxxxxxxxxxx) |
UK |
428-790-6 |
72963-72-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
790 |
5-xxxxx-2-(4-xxxxxxxxxxx)xxxxx (XXXX) |
XX |
429-290-0 |
3380-30-1 |
x |
x |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
807 |
(X)-1-[(2-xxxxxxxxxxxx-5-xx)xxxxxx]-3-xxxxxx-2-xxxxxxxxxxxxx (chlothianidin) |
DE |
433-460-1 |
210880-92-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
952 |
Xxxxxxxx sphaericus 2362, kmen XXXX-1743 |
IT |
xxxxxxxxxxxxxxx |
143447-72-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
955 |
Xxxxxxxx xxxxxxxxxxxxx xxxxx. xxxxxxxxxxx, xxxx SA3A |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
957 |
Bacillus xxxxxxxx |
XX |
xxxxxxxxxxxxxxx |
xxxx xxxxxxxxxx |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
928 |
5-xxxxx-2-xxxxxxxxxxxxxxxx-3(2X)-xx (Xxxxxx 247-500-7) x 2-methylisothiazol-3(2H)-on (Xxxxxx 220-239-6), xxxx (3:1) (xxxx XXXX/XXX) |
FR |
směs |
55965-84-9 |
|
x |
|
x |
|
x |
|
|
|
|
x |
x |
x |
|
|
|
|
|
939 |
aktivní xxxxx (xxxxxxxx xxxxxx xxxxxxxx xxxxxxx a xxxxxxxxx xxxxxxx xx xxxx) |
XX |
xxxx |
xxxx xxxxxxxxxx |
|
x |
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
813 |
peroxyoktanová kyselina |
XX |
xxxx xxxxxxxxxx |
33734-57-5 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1014 |
xxxxxxxx zeolit |
SE |
není relevantní |
není xxxxxxxxxx |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (x-xxxxxxxxx) |
IE |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
931 |
alkyltrimethylendiaminy, X-X12-14(xx xxxxx xxxxxx), xxxxxxxx xxxxxx s xxxxxxxxxxxx xxxxxxxxx (Ampholyt 20) |
XX |
xxxx xxxxxxxxxx |
139734-65-9 |
|
x |
x |
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
152 |
xxxxxxxx reakce 5,5-xxxxxxxxxxxxxxxxxx, 5-ethyl-5-methylhydantoinu s xxxxxx x chlorem (XXXXX) |
XX |
xxxx x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
459 |
xxxxxxx xxxx xxxxx xxxxxxxxxxxx x xxxxxxxx xxxxxxxxxx |
SE |
není x xxxxxxxxx |
xxxx k dispozici |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
777 |
xxxxxxx xxxxxxxx 5,5-xxxxxxxxxxxxxxxxxx, 5-xxxxx-5-xxxxxxxxxxxxxxxx x xxxxxxx (XXXXX) |
XX |
xxxx k dispozici |
xxxx x xxxxxxxxx |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
810 |
fosforečnanové xxxx x xxxxxxx xxxxxxx |
XX |
xxxx x xxxxxxxxx |
308069-39-8 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
824 |
stříbrno-zinečnatý zeolit |
XX |
xxxx x xxxxxxxxx |
130328-20-0 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1013 |
xxxxxxxx-xxxxxxx zeolit |
XX |
xxxx k dispozici |
130328-19-7 |
|
x |
|
x |
x |
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1017 |
stříbro xxxxxxxxxxx na xxxxx xxxxxxxxxx (xxxx nanomateriál xx xxxxx xxxxxxxxxx xxxxxxxx x xxxxxxxxxx částicemi xx xxxxxxxxxx) |
SE |
není x xxxxxxxxx |
není x xxxxxxxxx |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
1019 |
xxxx křemičitý (xxxx xxxxxxxxxxxx xxxxxxx xxxxxxxx x xxxxxxxxxx) |
XX |
xxxx k dispozici |
68909-20-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
831 |
xxxxxxxxx |
XX |
přípravek xx xxxxxxx xxxxxxx |
61790-53-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
854 |
(XX)-3-xxxx-2-xxxxx-4-xxxxxxxxxxxx-2-xxxx-(1X,3X;1X,3X)-2,2-xxxxxxx-3-(2-xxxxxxxxx-1-xxxx)-xxxxxxxxxxxxxxxxxxxxx (směs 4 xxxxxxx 1X xxxxx, 1X: 1X xxxxx, 1X: 1R xxx, 1X: 1X xxx, 1X 4:4:1:1) (x-xxxxxxxxx) |
XX |
xxxxxxxxx na xxxxxxx xxxxxxx |
231937-89-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
855 |
(XX)-3-xxxxx-2-xxxxxx-4-xxxxxxxxxxxx-2-xx-1-xx-(1X,3X)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (xxxx 2 xxxxxxxxxxxxx) (esbiothrin) |
XX |
xxxxxxxxx xx xxxxxxx xxxxxxx |
260359-57-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
848 |
X-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X′-xxxx-X-xxxxxxxxxxxxxxxxxxx (acetamiprid) |
XX |
přípravek xx xxxxxxx xxxxxxx |
160430-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
835 |
esfenvalerát/(S)-(3-fenoxyfenyl)kyanmethyl-(S)-2-(4-chlorfenyl)-3-methylbutanoát (xxxxxxxxxxxx) |
XX |
xxxxxxxxx na xxxxxxx xxxxxxx |
66230-04-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
836 |
[(3-xxxxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx (α-xxxxxxxxxxxx) |
BE |
přípravek na xxxxxxx rostlin |
67375-30-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
843 |
4-xxxx-2-(4-xxxxxxxxxx)-1-(xxxxxxxxxxxx)-5-(xxxxxxxxxxxxxx)xxxxxx-3-xxxxxxxxxxx (chlorfenapyr) |
PT |
xxxxxxxxx xx xxxxxxx rostlin |
122453-73-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
859 |
xxxxxxx X-xxxxxxxxxxxxxxxxx(XXXXXX 204-697-4) x (xxxxxxxxxxx)xxxxxxxx (XXXXXX 203-439-8)/xxxxxxxxx xxxxxxxxx xxxxxxx amonný (XX Xxxxxxx) |
XX |
polymer |
25988-97-0 |
|
x |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
863 |
poly(biguanid-1,5-diylhexan-1,6-diyl) (XXXX) |
XX |
polymer |
27083-27-8/32289-58-0 |
x |
x |
x |
x |
x |
x |
|
|
x |
|
x |
|
|
|
|
|
|
|
868 |
xxxx(xxxxxxxx-1,5-xxxxxxxxx-1,6-xxxx-xxxxxxxxxxxx) |
XX |
xxxxxxx |
91403-50-8 |
x |
x |
x |
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
869 |
α-[2-(xxxxxxxxxxxxxxxxxxx)xxxxx]-ω-[xxxxxxxxxxx(xxxxxxxxxx)-xxxxxxxxx] (Xxxxxx 26) |
IT |
polymer |
94667-33-1 |
|
x |
|
x |
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
872 |
X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxx-xxxxx/ α, α ′-(xxxxxxxxxxxxx)xxx[ω-xxxxxxxxx(xxxxxxxxxx)]-xxx xx (xxxxxxxxxxx betain) |
XX |
xxxxxxx |
214710-34-6 |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
ČÁST 2
Xxxxxxxxx xxxxxx látky x xxxx přípravku nepodporované xx xxx 4. xxxxx 2014
Tato xxxx xxxx xxxxxxx xxxxxxxx
— |
kombinace xxxxx a typu přípravku xxxxxxx x xxxxxxx xxxx, xxxxxx případných xxxxxxxxx, |
— |
xxxxxxxx xxxxxxxxx všech xxxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxx x xxxxxxx x xxxxx 1, xxxxx xxxx, xxxxx xxxx uvedeny x xxxxxxx, x |
— |
xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxx x xxxx xxxxxxxxx xxxxxxxxxxx xx 4. srpna 2014, x xxxxxxxx těch, xxxxx xxxx výslovně xxxxxxxxx. |
Xxxxxxxxx xxxxx x xxxx xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxx xx xxxx xxxxx xxxxx xxxxxxxxx xxxxxxxxxx x neschválení xxxxx xxxxxx 20, jestliže xxxxx xxxxx xxxxxx xxxxxxxx xx xxxxxxxx xxxxxx xx xxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxx xx. 14 xxxx. 3 xxxx xxxxx xx xxxxxx xxxxxxxx xxxxxxxxx podle xx. 17 xxxx. 4 nebo 5.
Xxxxx xxxxxxx |
Xxxxx xxxxx |
Členský xxxx zpravodaj |
Číslo XX |
Xxxxx XXX |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
17 |
18 |
19 |
21 |
22 |
1021 |
1,3-xxxxxxx-5,5-xxxxxxxxxxxxxxxxx (xxxx definovaný xxxxx položky 152) |
XX |
204-258-7 |
118-52-5 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
166 |
xxxxxx(xxxxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
204-526-3 |
122-18-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
167 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxx-xxxxxxx (xxx položka 948) |
|
204-527-9 |
122-19-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-351-5 |
139-07-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 |
xxxxxx(xxxxxxxx)xxxxxxxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
205-352-0 |
139-08-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227 |
2-(thiazol-4-yl)benzimidazol (xxxxxxxxxxxx) |
XX |
205-725-8 |
148-79-8 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
331 |
xxxxxxxxxxxxxxxxxxxxxx-xxxxxx (xxx xxxxxxx 949) |
|
219-234-1 |
2390-68-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
384 |
xxxxxxxx(xxxxxxx)xxxxxxx-xxxxxxx (xxx položka 949) |
|
226-901-0 |
5538-94-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
399 |
xxxxxx(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxx (xxx položka 948) |
|
230-698-4 |
7281-04-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
401 |
xxxxxxx |
XX |
231-131-3 |
7440-22-4 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
418 |
xxxx xxxxxxxxx amorfní |
XX |
231-545-4 |
7631-86-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
449 |
síran xxxxxxx |
XX |
231-847-6 |
7758-98-7 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1016 |
xxxxxxx xxxxxxxx |
SE |
232-033-3 |
7783-90-6 |
x |
x |
|
|
|
x |
x |
|
x |
x |
x |
|
|
|
|
|
|
|
554 |
4-[(xxxxxxxxxxx)xxxxxxxx]-1-xxxxxxxxxxxx |
XX |
243-468-3 |
20018-09-1 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
587 |
xxxxx(xxxxxxxx)xxxxxxxxxxxx-xxxxxxx (xxx xxxxxxx 949) |
|
251-035-5 |
32426-11-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
601 |
xxxxxxxxxxxxxx(xxxxxxx-9-xx-1-xx)xxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
253-363-4 |
37139-99-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
615 |
3-xxxxxxxxxxxx(1XX,3XX;1XX,3XX)-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (xxxxxxxxxx) |
XX |
258-067-9 |
52645-53-1 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
637 |
alkyl(benzyl)dimethylamonium-chloridy (xxxxx xxxxxxx xx xxxxxxxx kyselin kokosového xxxxx) (xxx xxxxxxx 948) |
|
263-080-8 |
61789-71-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
638 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx odvozen xx mastných xxxxxxx xxxxxxxxxx xxxxx) (xxx xxxxxxx 949) |
|
263-087-6 |
61789-77-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
639 |
xxxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (alkyl xxxxxxx xx hydrogenovaných xxxxxxxx xxxxxxx xxxx) (xxx položka 949) |
|
263-090-2 |
61789-80-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
647 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
264-151-6 |
63449-41-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
668 |
dialkyl(C6-C12)dimethylamonium-chloridy (xxx xxxxxxx 949) |
|
269-925-7 |
68391-06-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
670 |
xxxxx(X8-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
270-324-7 |
68424-84-0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
689 |
xxxxx(X10-X16)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxx xxxxxxx 948) |
|
273-544-1 |
68989-00-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
692 |
xxxxx(X10-X16)xxxxxxxxxxxxxxxxx |
XX |
274-687-2 |
70592-80-2 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
697 |
xxxxxxx(X8-X18)xxxxxxxxxxxxxx-xxxxxxxx (xxx xxxxxxx 949) |
|
277-453-8 |
73398-64-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1000 |
xxxxxxxxxx-xxx(xxxxxxxxxxxxxxxxx)xxxxxxxx xxxxxxxxxx |
XX |
279-013-0 |
14915-85-4 |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
998 |
xxxxxxx margosy jiný xxx x xxxxx xxxxxxxx Azadirachta xxxxxx xxxxxxxxxxx xxxxx a xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx |
XX |
283-644-7 |
84696-25-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
741 |
xxxxx(X8-X18)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxx (xxx xxxxxxx 948) |
|
293-522-5 |
91080-29-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1020 |
1,3-xxxxxxx-5-xxxxx-5-xxxxxxxxxxxxxxxxxx-2,4-xxxx (xxxx definovaný xxxxx položky 777) |
XX |
401-570-7 |
89415-87-2 |
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
778 |
1-(4-chlorfenyl)-4,4-dimethyl-3-[(1H-1,2,4-triazol-1-yl)methyl]pentan-3-ol (xxxxxxxxxxx) |
XX |
403-640-2 |
107534-96-3 |
|
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
805 |
xxxxxxx xxxxxxx xxxxxxxx-xxxxxxx, xxxxxxxx-xxxxxxxxx x xxxxxxxx-xxxxxxxxx x peroxidem xxxxxx (xxxxxxxx) |
XX |
432-790-1 |
xxxx xxxxxxxxxx |
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
923 |
xxxxx(xxxxxx)xxxxxxxxxxxxxxx-xxxxxxx/xxxxxxxxxxxx-xxxxxxx (viz xxxxxxx 948) |
|
směs |
8001-54-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
949 |
(xxxxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (alkyly (X6-X18) xxxxxxxx x xxxxxxxxxx, xxxxxxxx od xxxxxxxx xxxxxxx loje, xxxxxxxxxx xxxxx x xxxxxxxx xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx EINECS |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
950 |
xxxxxxxxxxxxxxxxxxxxx-xxxxxxxx, -xxxxxxx xxxx -xxxxxx-xxxxxxx) (xxxxxx (X8-X18) xxxxxxxx x nenasycené, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx oleje x sójového xxxxx) (XXXX) |
XX |
xxxx xxxxx xxxxxxxxx x xxxxxxx EINECS |
není xxxxxxxxxx |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
948 |
xxxxxx(xxxxx)xxxxxxxxxxxxxxx-xxxxxxxx, -bromidy xxxx -xxxxxxxxx) (xxxxxx (X8-X22) xxxxxxxx x xxxxxxxxxx, xxxxxxxx xx xxxxxxxx xxxxxxx xxxx, xxxxxxxxxx xxxxx a sójového oleje) (XXX) |
XX |
xxxx látek xxxxxxxxx x seznamu XXXXXX |
není xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
|
849 |
3-xxxxxxxxxxxx-(1X,3XX)-2,2-xxxxxxxx-3-(2-xxxxxxxxxx-1-xx-1-xx)xxxxxxxxxxx-1-xxxxxxxxxx (d-fenothrin) |
XX |
xxxx xxxxxxxxxx |
188023-86-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x |
|
|
|
1001 |
alkyl(C12-C16)benzyl(dimethyl)amonium-chloridy (xxxx xxx xxxxx xxxxxxxxx xxx položku 671) |
XX |
xxxx relevantní |
xxxx relevantní |
x |
x |
x |
x |
|
|
|
x |
|
x |
x |
x |
|
|
|
|
|
x |
1002 |
alkyl(C12-C18)benzyl(dimethyl)amonium-chloridy(jiné xxx látka spadající xxx položku 667) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1003 |
xxxxx(X12-X18)(xxxxxxxxxxx)xxxxxxxxxxxxxxx- xxxxxxxx (xxxx xxx látka xxxxxxxxx pod xxxxxxx 725) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1005 |
xxxxx(X12-X14)xxxxxx(xxxxxxxx)xxxxxxx-xxxxxxxx (xxxx xxx látka xxxxxxxxx xxx položku 724) |
XX |
xxxx relevantní |
není relevantní |
x |
x |
x |
x |
|
|
|
|
|
x |
x |
x |
|
|
|
|
|
x |
1006 |
fosforečnanové xxxx xxxxxxxxxx xxxxxxx, xxxxx, xxxxxx x xxx |
XX |
xxxx xxxxxxxxxx |
398477-47-9 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
1009 |
dialkyl(C8-C10)dimetylamonium-chloridy (jiné xxx xxxxx xxxxxxxxx xxx položku 673) |
XX |
xxxx xxxxxxxxxx |
xxxx xxxxxxxxxx |
x |
x |
x |
x |
x |
x |
|
|
|
x |
x |
x |
|
|
|
|
|
|
1011 |
xxxxx(xxxxxxxxx)xxxxxxx-xxxxxxxx (xxxxx xxxxxxx xx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxx) (xxxx než xxxxx xxxxxxxxx xxx xxxxxxx 635) |
XX |
xxxx xxxxxxxxxx |
xxxx relevantní |
|
|
|
|
|
|
|
x |
|
|
|
|
|
|
|
|
|
|
1012 |
hlinitokřemičitan xxxxx, xxxxxxxx a xxxxxxxxx xxxxxxx/xxxxxxxx-xxxxxxxxx xxxxxx |
SE |
xxxx xxxxxxxxxx |
130328-20-0 |
|
x |
|
|
|
|
x |
|
x |
|
|
|
|
|
|
|
|
|
598 |
(±)-1-(β-xxxxxxxx-2,4-xxxxxxxxxxxxxxxxx)xxxxxxxx (xxxxxxxx xxxxxxxxx) |
XX |
přípravek xx ochranu xxxxxxx |
73790-28-0 |
|
|
x |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
XXXXXXX XXX
Xxxxx
Xxxx xxxxxxxxx |
Xxxxx pro xxxxxxxxxx hodnotící xxxxxx xxxxx xx. 6 odst. 3 xxxx. x) |
Xxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxx xx. 7 xxxx. 2 xxxx. x) |
8, 14, 16, 18, 19 x 21 |
31.12.2015 |
31.3.2016 |
3, 4 x 5 |
31.12.2016 |
31.3.2017 |
1 x 2 |
31.12.2018 |
31.3.2019 |
6 x 13 |
31.12.2019 |
31.3.2020 |
7, 9 a 10 |
31.12.2020 |
31.3.2021 |
11, 12, 15, 17, 20 x 22 |
31.12.2022 |
31.9.2023 |